US EditionPublished • loading... • Updated
Costco to sell Ozempic, Wegovy for $499 a month
Costco offers a four-week supply of Ozempic and Wegovy for $499 to uninsured members, addressing gaps where 1 in 5 privately insured lack coverage for these medications.
- Novo Nordisk announced on October 3, 2025, that Costco will sell a month's supply of Wegovy and Ozempic for $499 at over 600 pharmacies nationwide.
- This partnership responds to high drug costs and insurance gaps, as many people lack coverage or cannot afford brand-name GLP-1 medications.
- David Moore, Novo Nordisk U.S. president, said the deal aims to provide 'real, authentic' medications where patients seek care, targeting lower socioeconomic groups.
- Experts note that although the $499 price cuts costs in half, it remains too expensive for many uninsured patients, with insurance-covered patients paying as little as $25 monthly.
- The discounted access may improve availability but likely will not fully solve barriers related to affordability and insurance coverage for the most vulnerable populations.
Insights by Ground AI
Podcasts & Opinions
27 Articles
27 Articles
The Independent+2 Reposted by 2 other sources
Costco to start selling Ozempic and Wegovy at discounted prices
The popular medications will be available at 600 Costco pharmacies
·London, United Kingdom
Read Full Article
Costco selling Ozempic, Wegovy — at discount for members
(NewsNation) — Popular GLP-1 prescription medications Ozempic and Wegovy will now be available at Costco for $499 a month. The company that makes Ozempic and Wegovy, Novo Nordisk, announced Friday that the injectable pens will be sold at Costco pharmacies for a monthly out-of-pocket cost of $499. For Costco members who have insurance, the price will vary. The medications are already available for $499 on Novo Nordisk's direct-to-consumer website…
Coverage Details
Total News Sources27
Leaning Left4Leaning Right0Center20Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
